CD4 and neoplasm: In immunocompetent mice implanted with subcutaneous Lewis lung cancer cells, GSK126 (EZH2i) treatment led to accumulation of myeloid-derived suppressor cells (MDSC) and decreased numbers of CD4+ T cells and CD8+ T cells, which masked the anti-tumour effects of EZH2i.